Signant Health

We support psychedelic #clinicaltrials with the methodological rigor and familiarity with the evolving regulatory landscape necessary to gain approvals. Explore our solutions and experience:➡️ https://hubs.li/Q02HM-2c0

Explore how computerized cognitive assessments in #oncologytrials revolutionize understanding Cancer-Related Cognitive Impairment (CRCI), transform trial protocols, and inform targeted interventions in our latest blog post by Viani Figueroa, PhD: https://hubs.li/Q02HtCfc0

Attention CROs! In our upcoming webinar, discover how a unified #eClinical platform gives you a competitive edge, enhances your offerings to sponsors, and streamlines site operations. Save your spot: https://hubs.li/Q02H4_XT0

Despite the potential benefits to patients, providers, and pharmaceutical companies, the absence of labeling related to Patient-Reported Outcome Measures has been striking. In this article in DIA's Global Forum, Anthony Todd Everhart, MD examines the challenges with PROMs in #cancertrials and proposes collaborative ways to overcome them: https://hubs.li/Q02GYbrR0

Look for us at #AAIC24 where we're discussing the role of cognitive assessments in #AlzheimersResearch and sharing interesting findings in these posters: 🌍 Geo-cultural Variation in MMSE Score Changes in Alzheimer's Trials 📊 MMSE and CDR Score Changes in Multinational Alzheimer's Trials 📑 Impact of Rater Change on MMSE Data: A Post-Hoc Analysis 📉 Impact of Site Size on Data Quality in Early Alzheimer's Disease Clinical Trials Meet our experts and get resources: https://hubs.li/Q02GLX_S0

Signant is pleased to announce the appointment of industry veteran Paul Richmond to chief commercial officer. Read how Paul will help guide our biotech, pharma, and CRO customers with selecting the right #eClinical solutions for their trials: https://hubs.li/Q02Gy7h80

In this perspective paper, Signant's Bill Byrom and industry colleagues explore opportunities, challenges, and strategies for leveraging sensor-based functional outcomes (SFBO) in #clinicaltrials. Explore their strategies and insights for optimizing evidence generation using SFBOs alongside other COAs: https://hubs.li/Q02G0nkP0 #digitalhealth

In our latest blog, Maria Visser and Martina Micaletto discuss the subjectivity of instruments used to measure #atopicdermatitis severity, the importance of data accuracy, and how different assessment methods can impact trial outcomes. Read more: https://lnkd.in/e4Y2VJKw #ClinicalTrials #DermatologyResearch

Discover a simpler #clinicaltrial experience without compromising quality or functionality with Signant SmartSignals® Unified Platform. Say goodbye to managing multiple systems and vendors for each trial. Learn more: https://hubs.li/Q02Ffn7m0

In this podcast, Signant's Bill Byrom PhD, speaks with Julian Minett, CEO of Spencer Group, about the use of #AI and #MachineLearning in clinical #drugdevelopment. While covering a breadth of topics and application areas, one promising area they examine is how AI can be a useful tool in COA development and implementation, using case study illustrations. Listen now: https://hubs.li/Q02F3kVd0